Should I buy Cigna (CI) stock or is it too late?

Cigna · Health Care · price $278

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Jefferies — 72% of its targets hit on this sector (380 calls tested). It aims for $307 (+11 %), call made on August 5, 2026, maturing on August 5, 2027 (23 d ago).

The 7 reliable analysts $320+15 %

The 6 other firms $351+26 %

How to read it: the 7 reliable firms are not filtered by optimism — 7 aim above the price, 0 below, hence their $320 median. “The 6 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Cigna

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Deutsche Bank	74 %	+23.7 %	23	$302 +9%
Jefferies	100 %	+23.7 %	10	$307 +11%
Raymond James	67 %	+16.2 %	18	$320 +15%
JP Morgan	58 %	+16.1 %	12	$375 +35%
UBS	80 %	+13.7 %	10	$400 +44%
Mizuho	64 %	+9.8 %	11	$340 +22%
Morgan Stanley	64 %	+9.6 %	25	$361 +30%
Stephens & Co.	64 %	+6.7 %	11	$380 +37%

In short — Should you invest in Cigna? Is it too late, still worth it? Analysts are fairly positive (69% buy, median target $340, i.e. +22%), and the most reliable on CI targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

69% of analysts rate it a buy (Buy consensus, 13 ratings) — a sign of market conviction.
Median price target $340, i.e. +22% from the current price ($278).
The most reliable firm on CI, Jefferies (100% hit rate, 10 scored calls), targets $307 (call made on August 4, 2026, maturing on August 4, 2027) (+11%) in its most recent call, and $330 (call made on April 20, 2026, maturing on April 20, 2027) (+19%) in the one coming due soonest.
Pays a dividend (2.2% yield), raised for 5 years — regular income on top of potential upside.
Reasonable valuation (P/E ~11) relative to its sector.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 4 are neutral.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on CI

Median target $340 (+22%) · 13 ratings · Buy consensus

Strong Buy00%

Buy969%

Hold431%

Sell00%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Cigna now?

We won't decide for you. The facts: 69% of analysts rate it a buy, median target $340 (+22%), and Jefferies (most reliable on CI, 100%) targets $307. Weigh that against valuation (P/E ~11). This is not personalized advice.

Is it too late to invest in Cigna?

Not according to analysts: the median target ($340) is still +22% above the current price ($278) (most reliable on CI: Jefferies, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Cigna still worth investing in?

It depends on the gap between the price ($278) and its estimated value: analysts target $340 on median (+22%), with 69% buys (most reliable on CI: Jefferies, 100%). Cross-check with their real reliability on CI and the cautions above. Information, not advice.

What's the main risk in buying CI?

The consensus is not unanimous: of 13 ratings, 4 are neutral.

→ Go deeper: the full Cigna profile (consensus, analyst reliability, price target, performance).